Be Part of the Pulmonary Fibrosis Foundation’s Virtual Walk

Resokine Protein Reduced Lung Disease in Mice, aTyr Will Report at Conference

The resokine protein reduced interstitial lung disease (ILD) in mice, according to one of two presentations that aTyr Pharma will make at the American Thoracic Society International Conference in Washington, which starts today. Atry derived its Resolaris therapy from resokine, which helps prevent the immune system from turning against healthy cells. Scientists…

9 Tips to Lower Your Risk of Lung Disease

Lung disease is one of the main causes of American deaths, second only to heart disease. While some lung diseases are genetic and unavoidable, following a healthy lifestyle and avoiding lung irritants can help protect you from developing many of them. We’ve put together a list of tips to help lower your risk of developing a…

Genoa Secures $62 Million to Fund Phase 2 Trial of Inhaled Aerodyne for Idiopathic Pulmonary Fibrosis

Genoa Pharmaceuticals has completed a $62 million Series A financing round to pursue a Phase 2 clinical trial of Aerodone (inhaled pirfenidone) to treat idiopathic pulmonary fibrosis (IPF). The Seattle-based company also appointed Dr. Ketan Patel, Dr. Naveed Siddiqi, Tiba Aynechi, Niall O’Donnell and Dr. Heather Preston to its board of directors. Dr. Jonathan Leff,…

Putting Financial Affairs in Order

Part of facing that I have a terminal illness involves putting my financial affairs in order. I don’t want to leave my husband and adult children with the burden of having to sort out financial problems when I pass away. They will have too much to deal…

The Two Main Types of Pulmonary Fibrosis

Pulmonary fibrosis is a chronic, progressive lung disease where the tissue in the lungs becomes scarred and thickens over time. This thickening (or fibrosis) leads to stiffness in the lungs which makes it difficult for oxygen to pass through the air sacs (alveoli) and into the blood stream. There are…